VALIANTLAB

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURY
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity0.13-0.94-1.05-1.05
Return on Assets0.09-0.55-0.70-0.70
Return on Capital Employed-3.31-1.980.100.10
Return on Invested Capital-1.57-1.930.044.98
Margins
EBITDA Margin-4.62-3.512.6910.87
Operating Margin-5.70-5.080.150.15
Incremental Operating Margin-7.406.84
Pretax Margin-0.42-1.130.328.02
Net Income Margin0.18-1.65-1.385.23
Net Income to Common Margin0.18-1.65-1.385.23
FCF Margin-24.16-84.37-18.79-18.79
Additional
Effective Tax Rate141.53-45.52525.4034.73
Sustainable Growth Rate0.13-0.94-1.05-1.05
Incremental Operating Margin %-7.406.8435.85
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.